Sanofi SAN-1.02%decrease; red down pointing triangle posted better-than-expected earnings and sales in the third quarter, ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

Products will be made at six of Sanofi’s European API production sites ... Management is trying to decide further details such as whether to list the separated business on the Euronext Paris ...

Sanofi is aiming to sign an agreement this weekend to sell control of its consumer health business to Clayton Dubilier & Rice, following a last-ditch attempt by a rival bidder to derail the deal ...

Sanofi is now in “exclusive negotiations ... Some of its most popular products include the antihistamine Allegra, non-opioid pain reliever Doliprane, stomach cramp reliever Buscopan, Selsun ...

Sanofi records global net product sales of Dupixent ... You can see the complete list of today’s Zacks #1 Rank stocks here. Estimates for Lilly’s 2024 earnings have risen from $13.79 to ...

Six years ago, Sanofi gave $125 million and promised over $1 billion in milestone payments to buzzy neuroscience startup ...

PARIS, Oct 11 (Reuters) - Sanofi (SASY.PA), opens new tab has entered into talks to sell a controlling 50% stake in its consumer health business Opella to U.S. private equity firm Clayton Dubilier ...

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for ...

US planemaker Boeing is heading into a busy week, with investors watching developments closely around its costly labour strike, as well as its latest quarterly results. More than 33,000 unionised ...

The French government has taken a small stake in Sanofi's consumer healthcare business ... Shares in Tata Consumer Products, which owns brand such as Tetley, slumped nearly 7% on Monday.